TY - JOUR
T1 - The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis
AU - Heslinga, S. C.
AU - Konings, T. C.
AU - van der Horst-Bruinsma, I. E.
AU - Kamp, O.
AU - van Halm, V. P.
AU - de Bruin-Bon, H. A. C. M.
AU - Peters, M. J.
AU - Nurmohamed, M. T.
PY - 2018
Y1 - 2018
N2 - Background: Diastolic left ventricular (LV) dysfunction appears more prevalent in ankylosing spondylitis (AS). The effects of tumor necrosis factor alpha (TNF-α) blocking therapy, a strong and effective anti-inflammatory drug, on diastolic LV function in AS are unknown. The objective of the study was to find the effects of 1-year treatment with golimumab 50 mg subcutaneously once per month on systolic and diastolic LV dysfunction in AS patients. Methods: Forty consecutive AS patients were treated with TNF-α blocking therapy for 1 year. Transthoracic echocardiography was performed in all patients at baseline and after 1 year of treatment. Results: Diastolic LV function improved after treatment in four out of six (67%) AS patients who completed follow-up (P=0.125), and did not develop or worsen in any of the other patients. Treatment with TNF-α blocking therapy had no effect on systolic LV function. Conclusion: These findings give support to the hypothesis that diastolic LV dysfunction improves during treatment with TNF-α blocking therapy.
AB - Background: Diastolic left ventricular (LV) dysfunction appears more prevalent in ankylosing spondylitis (AS). The effects of tumor necrosis factor alpha (TNF-α) blocking therapy, a strong and effective anti-inflammatory drug, on diastolic LV function in AS are unknown. The objective of the study was to find the effects of 1-year treatment with golimumab 50 mg subcutaneously once per month on systolic and diastolic LV dysfunction in AS patients. Methods: Forty consecutive AS patients were treated with TNF-α blocking therapy for 1 year. Transthoracic echocardiography was performed in all patients at baseline and after 1 year of treatment. Results: Diastolic LV function improved after treatment in four out of six (67%) AS patients who completed follow-up (P=0.125), and did not develop or worsen in any of the other patients. Treatment with TNF-α blocking therapy had no effect on systolic LV function. Conclusion: These findings give support to the hypothesis that diastolic LV dysfunction improves during treatment with TNF-α blocking therapy.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85060609887&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30510398
U2 - https://doi.org/10.2147/BTT.S176806
DO - https://doi.org/10.2147/BTT.S176806
M3 - Article
C2 - 30510398
SN - 1177-5475
VL - 12
SP - 143
EP - 149
JO - Biologics
JF - Biologics
ER -